Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: Analysis of 344 patients

Bone Marrow Transplantation

Volumn 49, Issue 1, 2014, Pages 17-23

  Bryant, A ^a   Nivison Smith, I ^b   Pillai, E S ^c   Kennedy, G ^c   Kalff, A ^c   Ritchie, D ^c   George, B ^d   Hertzberg, M ^d   Patil, S ^e   Spencer, A ^e   Fay, K ^a,f   Cannell, P ^g   Berkahn, L ^h   Doocey, R ^h   Spearing, R ⁱ   Moore, J ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b NSW Office of Environment and Heritage NSW   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e ALFRED HOSPITAL   (Australia)

^f ROYAL NORTH SHORE HOSPITAL   (Australia)

^g ROYAL PERTH HOSPITAL   (Australia)

^h AUCKLAND CITY HOSPITAL   (New Zealand)

ⁱ Christchurch City Council   (New Zealand)

Author keywords

Haematology; Leukaemia; Lymphoma; Reduced intensity conditioning

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN; FLUDARABINE; MELPHALAN; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; DISEASE CONTROL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; AUSTRALIA; BONE MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELOABLATIVE AGONISTS; NEW ZEALAND; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VIDARABINE; YOUNG ADULT;

EID: 84891877474     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.142     Document Type: Article

References (23)

1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813-1826.
2. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
3. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304-2312.
4. Dreger P, Brand R, Milligan D, Corradini P, Finke J, Lambertenghi Deliliers G et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 2005; 19: 1029-1033.
5. Unrelated Donor Haematopoietic Stem Cell Transplants in Australia 2001-2010A report from the Australasian Bone Marrow Transplant Recipients Registry November 2011.
6. Nivison-Smith I, Bradstock KF, Dodds AJ, Hawkins PA, Ma DD, Moore JJ et al. Hematopoietic stem cell transplantation in Australia and New Zealand, 1992-2004. Biol Blood Marrow Transplant 2007; 13: 905-912.
7. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele H et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006; 37: 439-449.
8. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
9. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reducedintensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367-369.
10. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994, Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
11. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
12. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312-1320.
13. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
14. Sarosy G, Leyland-Jones B, Soochan P, Cheson BD. The systemic administration of intravenous melphalan. J Clin Oncol 1988; 6: 1768-1782.
15. Delgado J, Thomson K, Russell N, Ewing J, Stewart W, Cook G et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 2006; 107: 1724-1730.
16. de Lima M, Champlin RE, Thall PF, Wang X, Martin 3rd TG, Cook JD et al. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia 2008; 22: 258-264.
17. Craddock C, Nagra S, Peniket A, Brookes C, Buckley L, Nikolousis E et al. Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2010; 95: 989-995.
18. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 2007; 13: 454-462.
19. Moore J, Nivison-Smith I, Goh K, Ma D, Bradstock K, Szer J et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2007; 13: 601-607.
20. Luger SM, Ringden O, Zhang MJ, Perez WS, Bishop MR, Bornhauser M et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012; 47: 203-211.
21. Delgado J, Pillai S, Benjamin R, Caballero D, Martino R, Nathwani A et al. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2008; 14: 1288-1297.
22. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865-3871.
23. Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G et al. T-celldepleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010; 28: 3695-3700.